Corrigendum to “Association of White Matter Integrity with Executive Function and Antidepressant Treatment Outcome in Patients with Late-Life Depression” [The American Journal of Geriatric Psychiatry 29 (2021) 1188-1198]

The authors regret an omission from the published study methodology. As described in the published manuscript, current treatment with antidepressant medication was an exclusion criterion for the clinical trial whose data were analyzed. We wish to clarify that while current treatment with antidepressant medication was an exclusion criterion, otherwise eligible individuals who were taking ineffective antidepressant medication were allowed to sign consent and participate in the study so long as they completed a study-supervised taper and discontinuation of the medication prior to beginning the study medication. Of the 71 analyzed participants in this publication, 18 individuals completed a study-supervised taper and discontinuation of ineffective antidepressant medication. The authors would like to apologize for any inconvenience caused. Association of White Matter Integrity With Executive Function and Antidepressant Treatment Outcome in Patients With Late-Life DepressionThe American Journal of Geriatric PsychiatryVol. 29Issue 12PreviewTwo contributing factors to antidepressant treatment nonresponse are the presence of white matter hyperintensities (WMHs) seen on T2-weighted magnetic resonance imaging (MRI) scans1 and executive dysfunction.2 WMHs are observed in the majority of older adults with depression, are associated with a more chronic clinical course,1 and predict lower response to antidepressant treatment.3 Executive dysfunction is common in late-life depression (LLD) and also predicts poorer response to antidepressant medication and higher relapse rates. Full-Text PDF